Bora Pharmaceuticals Completes $122.5M Acquisition of MacroGenics’ Rockville Manufacturing Operations

Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) has finalized its acquisition of MacroGenics, Inc.’s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and a warehousing center in Frederick, Maryland, for $122.5 million. The transaction, completed through its wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO service agreement with MacroGenics.

The acquisition bolsters Bora Biologics’ US manufacturing capacity to 20,000 liters of single-use bioreactor (SUB) drug substance capacity across two active US sites—Rockville and San Diego—and a development facility in Zhubei, Taiwan. This expansion positions Bora as a key player in the biologics contract development and manufacturing organization (CDMO) space, offering end-to-end services from development to commercial supply.

“This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply,” said Bobby Sheng, Chairman and CEO of Bora Group. “As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure.”

With the addition of the Rockville site, Bora Biologics now supports more than four active commercial programs, has completed over 120 GMP batches, and supplies multiple global markets including the US, EU, Japan, Canada, and the UK. The company also boasts fully integrated QC and analytical capabilities.

The combined US network has undergone five FDA inspections, including two at the Rockville facility and one PMDA review in 2025, all with clean results. Overall, the platform has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency for biotech and pharmaceutical companies.

Bora Group plans to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months. This integration aims to offer a seamless, fully integrated development-through-commercial biologics solution. The move underscores Bora’s commitment to expanding its biologics footprint and meeting the growing demand for domestic manufacturing capacity.

For more information about Bora Pharmaceuticals, visit https://www.bora-corp.com and https://www.boracdmo.com.

This news story relied on content distributed by Media Outreach. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Bora Pharmaceuticals Completes $122.5M Acquisition of MacroGenics’ Rockville Manufacturing Operations.

The post Bora Pharmaceuticals Completes $122.5M Acquisition of MacroGenics’ Rockville Manufacturing Operations appeared first on citybuzz.